Mark Walters, MD
Thursday, May 4, 2023, 8:00-9:00 am (San Francisco) Check your time zone
In this session Dr. Walters will discuss:
- Current results of unrelated donor hematopoietic stem cell transplantation (URD HCT) for thalassemia and key determinants that determine outcome
- URD HCT vs gene therapy for transfusion dependent thalassemias (TDT) with regard to accessibility and other considerations
- Key curative endpoints in curative therapies for TDT